

Aubagne, France; Bratislava, Slovakia | July 9, 2025

## Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform

- New partnership to advance cell-based mRNA production
- Sartorius to support GMP readiness through integrated process development and facility design
- Expansion planned across Europe and North America

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU). The two companies will jointly advance the industrialization and scale-up of Sensible's first-in-class cell-based platform for the design, optimization, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the next generation of mRNA medicines.

As part of the agreement, Sartorius Stedim Biotech has already provided significant support through advanced equipment and consumables. The partnership will extend to process development, closed-system facility design, and technical support to rapidly establish Sensible's GMP-compliant mRNA production capabilities. These activities will enable Sensible to expand the production from Slovakia to the US, UK, and broader Europe.

"Sartorius Stedim Biotech has played a vital role in enabling global biologics manufacturing - from vaccines to gene therapies - and we are honored to work with them to build the industrial backbone to unlock the next generation of mRNA therapeutics," said Miroslav Gašpárek, CEO and Co-Founder of Sensible Biotechnologies. "This partnership is a critical milestone in Sensible's journey to deliver first-in-class clinical-grade mRNA manufactured in living cells with unprecedented purity and performance, which is required for therapeutic applications of mRNA."

"We are excited to support Sensible in scaling a disruptive, cell-based approach to mRNA production," said Dr. René Fáber, CEO of Sartorius Stedim Biotech SA. "We believe that Sensible's unique platform will deliver mRNA with the superior quality needed for emerging mRNA therapeutics, while also supporting a more resilient and flexible biomanufacturing ecosystem in Europe and globally."

The MoU also outlines potential areas for deeper collaboration, reflecting both companies' commitment to enabling scalable, high-quality mRNA manufacturing worldwide.

### **A profile of Sartorius Stedim Biotech**

Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe.

Visit our [Newsroom](#) or follow us on [LinkedIn](#).

### **About Sensible Biotechnologies, Inc.**

Sensible Biotechnologies is developing the first cell-based platform for the design, optimization, and manufacturing of highly functional, low-immunogenic mRNA, unlocking the therapeutic potential of mRNA for pharma and biotech partners across a wide range of applications. Based in Boston, Oxford and Bratislava, Sensible has raised more than \$13M from leading life science and deep tech investors, including Recode Ventures, BlueYard Capital, Kaya VC, Backed VC, Y Combinator, ZAKA VC, and Onsite – the VC fund founded by the co-founder of BioNTech, Christoph Huber, and the co-founder of ARM, Hermann Hauser.

**More information on Sensible Biotechnologies:** [mRNA. Made better.](#)

### **Contact**

Lars Hanf  
Head of BPS Marketing Communications  
+491759558820  
[Lars.Hanf@Sartorius.com](mailto:Lars.Hanf@Sartorius.com)